<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39218877</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>A case report of prolonged viral shedding of SARS-CoV-2 in a patient who receive ibrutinib for CLL therapy.</ArticleTitle><Pagination><StartPage>895</StartPage><MedlinePgn>895</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">895</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-09794-z</ELocationID><Abstract><AbstractText>Patients on B cell immunosuppressive treatments have been shown to have persistent infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this report, a woman treated with ibrutinib for chronic lymphocytic leukemia experienced more than 40&#xa0;days of coronavirus disease 2019 (COVID-19) infection. Unexpectedly, her peripheral blood experiments showed a normal SARS-CoV-2-specific antibody level and a relatively elevated percentage of CD19&#x2009;+&#x2009;B cells, while an obvious decrease in the percentages of NK cells, CD4&#x2009;+&#x2009;T cells and CD8&#x2009;+&#x2009;T cells. Further SARS-CoV-2-specific T cell analysis in this patient indicated a significant decrease in the percentage of SARS-CoV-2-specific IFN-&#x3b3;, TNF-&#x3b1; or IL-2 producing CD4&#x2009;+&#x2009;T or CD8&#x2009;+&#x2009;T cells. Most notably, ten days after the cease of ibrutinib, the PCR for SARS-CoV-2 turned negative and the reduced proportions of peripheral CD4&#x2009;+&#x2009;T cells and CD8&#x2009;+&#x2009;T cells recovered. Our research predicted that the depleted B-cell function therapies may play considerable role in the development of long COVID-19 and the abnormal T-cell subset distribution might be the underlying mechanism.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ma</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Sixth People's HospitalAffiliated to, Shanghai Jiao Tong University School of Medicine , Shanghai, 200233, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wei</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Sixth People's HospitalAffiliated to, Shanghai Jiao Tong University School of Medicine , Shanghai, 200233, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xi</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Sixth People's HospitalAffiliated to, Shanghai Jiao Tong University School of Medicine , Shanghai, 200233, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Sixth People's HospitalAffiliated to, Shanghai Jiao Tong University School of Medicine , Shanghai, 200233, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Sixth People's HospitalAffiliated to, Shanghai Jiao Tong University School of Medicine , Shanghai, 200233, China. chenxiaohua2000@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Shanghai Sixth People's HospitalAffiliated to, Shanghai Jiao Tong University School of Medicine , Shanghai, 200233, China. chenjie123456@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1X70OSD4VX</RegistryNumber><NameOfSubstance UI="C551803">ibrutinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>JAC85A2161</RegistryNumber><NameOfSubstance UI="D000225">Adenine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000225" MajorTopicYN="Y">Adenine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015451" MajorTopicYN="Y">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="Y">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="Y">Virus Shedding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chronic lymphocytic leukemia</Keyword><Keyword MajorTopicYN="N">Immunosuppressive treatment</Keyword><Keyword MajorTopicYN="N">Prolonged viral shedding</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>1</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39218877</ArticleId><ArticleId IdType="pmc">PMC11367913</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-09794-z</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-09794-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488&#x2013;94. 10.1001/jama.2020.3204</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.3204</ArticleId><ArticleId IdType="pmc">PMC7054855</ArticleId><ArticleId IdType="pubmed">32125362</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 2020;383(26):2586&#x2013;8. 10.1056/NEJMc2031670</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031670</ArticleId><ArticleId IdType="pmc">PMC7722690</ArticleId><ArticleId IdType="pubmed">33259154</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335&#x2013;7. 10.1016/S1470-2045(20)30096-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 2020;95(8):E199&#x2013;203. 10.1002/ajh.25851</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25851</ArticleId><ArticleId IdType="pmc">PMC7267481</ArticleId><ArticleId IdType="pubmed">32356356</ArticleId></ArticleIdList></Reference><Reference><Citation>Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton&#x2019;s tyrosine kinase. Future Oncol. 2014;10(6):957&#x2013;67. 10.2217/fon.14.51</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon.14.51</ArticleId><ArticleId IdType="pmc">PMC4632638</ArticleId><ArticleId IdType="pubmed">24941982</ArticleId></ArticleIdList></Reference><Reference><Citation>Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstr&#xf6;m&#x2019;s macroglobulinemia. N Engl J Med. 2015;372(15):1430&#x2013;40. 10.1056/NEJMoa1501548</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1501548</ArticleId><ArticleId IdType="pubmed">25853747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Dhillon S. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015;75(7):769&#x2013;76. 10.1007/s40265-015-0380-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-015-0380-3</ArticleId><ArticleId IdType="pubmed">25802231</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ, Mato AR. BTK Inhibitors in Cancer Patients with COVID-19: &#x201c;The Winner Will be the One Who Controls That Chaos&#x201d; (Napoleon Bonaparte). Clin Cancer Res. 2020;26(14):3514&#x2013;6. 10.1158/1078-0432.CCR-20-1427</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-1427</ArticleId><ArticleId IdType="pmc">PMC7367762</ArticleId><ArticleId IdType="pubmed">32345646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134&#x2013;43. 10.1182/blood.2020006965</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006965</ArticleId><ArticleId IdType="pmc">PMC7472711</ArticleId><ArticleId IdType="pubmed">32688395</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarf&#xf2; L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354&#x2013;63. 10.1038/s41375-020-0959-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0959-x</ArticleId><ArticleId IdType="pmc">PMC7347048</ArticleId><ArticleId IdType="pubmed">32647324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin AY, Cuttica MJ, Ison MG, Gordon LI. Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review. EJHaem. 2020;1(2):596&#x2013;600. 10.1002/jha2.98</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jha2.98</ArticleId><ArticleId IdType="pmc">PMC7537222</ArticleId><ArticleId IdType="pubmed">33043320</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorcari S, Atene CG, Maffei R, Debbia G, Potenza L, Luppi M, et al. Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. Haematologica. 2021;106(8):2265&#x2013;8. 10.3324/haematol.2020.277392</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2020.277392</ArticleId><ArticleId IdType="pmc">PMC8327720</ArticleId><ArticleId IdType="pubmed">33691383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SEM, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213&#x2013;9. 10.1182/blood-2015-04-639203</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-04-639203</ArticleId><ArticleId IdType="pmc">PMC4635117</ArticleId><ArticleId IdType="pubmed">26337493</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32&#x2013;42. 10.1056/NEJMoa1215637</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215637</ArticleId><ArticleId IdType="pmc">PMC3772525</ArticleId><ArticleId IdType="pubmed">23782158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei D, Chen Y, Yu X, Lai YD, Xu W, Ji P, et al. Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination. Emerging microbes &amp; infections. 2022;11(1):2474&#x2013;84. 10.1080/22221751.2022.2130101</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2130101</ArticleId><ArticleId IdType="pmc">PMC9621266</ArticleId><ArticleId IdType="pubmed">36166417</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi G, Rocchetti C, Magri R, Uccelli S, Bottone D, Quadri F, et al. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. Monaldi Arch Chest Dis. 2021;91(4).</Citation><ArticleIdList><ArticleId IdType="pubmed">34121379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Kanemasa Y, Atsuta Y, Fujiwara S, Tanaka M, Fukushima K, et al. Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo. Japan Int J Clin Oncol. 2021;26(3):485&#x2013;93. 10.1007/s10147-020-01837-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10147-020-01837-0</ArticleId><ArticleId IdType="pmc">PMC7680712</ArticleId><ArticleId IdType="pubmed">33225396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao S, Lian J, Lu Y, Jia H, Hu J, Yu G, et al. Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study. J Infect Dis. 2020;222(3):367&#x2013;71. 10.1093/infdis/jiaa311</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa311</ArticleId><ArticleId IdType="pmc">PMC7542891</ArticleId><ArticleId IdType="pubmed">32474608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacova B, Kohutova Z, Zubata I, Gaherova L, Kucera P, Heizer T, et al. Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab. Clin Exp Med. 2023;23(2):371&#x2013;9. 10.1007/s10238-022-00809-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-022-00809-0</ArticleId><ArticleId IdType="pmc">PMC8963888</ArticleId><ArticleId IdType="pubmed">35352210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54(6):1257&#x2013;1275.e1258. 10.1016/j.immuni.2021.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarbartolo S, Ranzani V, Bandera A, Gruarin P, Bevilacqua V, Putignano AR, et al. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci Immunol. 2021;6(62):eabg5021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34376481</ArticleId></ArticleIdList></Reference><Reference><Citation>Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis. 2021;223(1):23&#x2013;7. 10.1093/infdis/jiaa666</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa666</ArticleId><ArticleId IdType="pmc">PMC7797758</ArticleId><ArticleId IdType="pubmed">33089317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, et al. Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. Cancer Discov. 2022;12(1):62&#x2013;73. 10.1158/2159-8290.CD-21-1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1033</ArticleId><ArticleId IdType="pmc">PMC8758535</ArticleId><ArticleId IdType="pubmed">34753749</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Chinchilla C, Vazquez-Montero L, Palaz&#xf3;n-Carri&#xf3;n N, Fern&#xe1;ndez-Rom&#xe1;n IM, L&#xf3;pez-Barba J, de la Cruz-Merino L, et al. Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases. Front Immunol. 2022;13: 860891. 10.3389/fimmu.2022.860891</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.860891</ArticleId><ArticleId IdType="pmc">PMC9046988</ArticleId><ArticleId IdType="pubmed">35493500</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>